Co-designing new tools for collecting, analysing and presenting patient experience data in NHS services: working in partnership with patients and carers

Abstract

Background The way we collect and use patient experience data is vital to optimise the quality and safety of health services. Yet, some patients and carers do not give feedback because of the limited ways data is collected, analysed and presented. In this study, we worked together with researchers, staff, patient and carer participants, and patient and public involvement and engagement (PPIE) contributors, to co-design new tools for the collection and use of patient experience data in multiple health settings. This paper outlines how the range of PPIE and research activities enabled the co-design of new tools to collect patient experience data. Methods Eight public contributors represented a range of relevant patient and carer experiences in specialist services with varied levels of PPIE experience, and eleven members of Patient and Participation Groups (PPGs) from two general practices formed our PPIE group at the start of the study. Slide sets were used to trigger co-design discussions with staff, patient and carer research participants, and PPIE contributors. Feedback from PPIE contributors alongside verbatim quotes from staff, patient and carer research participants is presented in relation to the themes from the research data. Results PPIE insights from four themes: capturing experience data; adopting digital or non-digital tools; ensuring privacy and confidentiality; and co-design of a suite of new tools with guidance, informed joint decisions on the shaping of the tools and how these were implemented. Our PPIE contributors took different roles during co-design and testing of the new tools, which supported co-production of the study. Conclusions Our experiences of developing multiple components of PPIE work for this complex study demonstrates the importance of tailoring PPIE to suit different settings, and to maximise individual strengths and capacity. Our study shows the value of bringing diverse experiences together, putting patients and carers at the heart of improving NHS services, and a shared approach to managing involvement in co-design, with the effects shown through the research process, outcomes and the partnership. We reflect on how we worked together to create a supportive environment when unforeseen challenges emerged (such as, sudden bereavement).

Using consumer engagement strategies to improve healthcare safety for young people: An exploration of the relevance and suitability of current approaches

“…25,26 The benefit of digital technologies to foster ongoing connection was identified in our study reinforcing this is an area for further investigation. 29 The responsibility of service providers to develop relationships with young people to tailor communication in cancer care has been highlighted, 27 as having the benefits of establishing a consistent point of contact within the healthcare service for young people to access between appointments through interventions such as cancer navigators. 24 Collaborative research is required to increase understanding about the strategies that may be effective to facilitate engagement, and how young people can be equipped to raise safety issues.…”

Realizing the Potential of Social Determinants Data: A Scoping Review of Approaches for Screening, Linkage, Extraction, Analysis and Interventions

“…They should ensure that the data utilized to inform interventions is collected directly from the population undergoing the intervention. Utilizing a pilot survey to pre-test a data collection instrument in line with a co-design methodology is suggested [248,249]. Co-designing is a collaborative effort aimed at establishing a conduit for vulnerable individuals to develop a more supportive environment, thereby mitigating the occurrence of unanticipated obstacles.…”

Building from Patient Experiences to Deliver Patient-Focused Healthcare Systems in Collaboration with Patients: A Call to Action

“…In June 2021, the European Medicines Agency (EMA) proposed guidelines for incorporating patient experience to better inform regulatory decision making [ 47 ], meaning that, like the FDA, it recognizes the importance of developing a PXD strategy early in medicines and devices development. Although around 70% of NDAs include PXD [ 37 ], not all PXD are created equal; many tools that capture patient experience have not been developed in partnership with patients [ 48 ] and the validity and reliability of different tools vary [ 49 ]. Tools or metrics to evaluate the impact of health-related conditions on patients should also consider immediate and longer-term impact.…”